Factors associated with early mortality in non-small cell lung cancer patients following systemic anti-cancer therapy: A 10 year population-based study-Reference-Cited by-同舟云学术

Factors associated with early mortality in non-small cell lung cancer patients following systemic anti-cancer therapy: A 10 year population-based study

Published:2019-08 Issue: Volume:134 Page:141-146
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Gibson Amanda J.W.^ORCID,Li Haocheng,D’Silva Adrijana^ORCID,Elegbede Anifat A.^ORCID,Tudor Roxana A.,Otsuka Shannon,Bebb D. Gwyn,Cheung Winson Y.

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference39 articles.

1. Chemotherapy for non-small-cell lung cancer part 1 and part 2;Novello;Oncology,2003

2. Systemic chemotherapy for non-small cell lung Cancer: recent advances and future directions;Ramalingam;Oncologist,2008

3. Variations in intensity of end-of-Life Cancer therapy by Cancer type at a Canadian Tertiary Cancer Centre between 2003 and 2010;Grendarova;Support. Care Cancer,2015

4. 30-day morality after systemic anti-cancer treatment for breast and lung cancer in England: a population-based observational study;Wallington;Lancet,2016

5. Peri-operative mortality rate (POMR): a global indicator of access to safe surgery and anesthesia;Watters;World J. Surg.,2015

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lung cancer mortality and associated predictors: systematic review using 32 scientific research findings;Frontiers in Oncology;2023-12-14

2. Early mortality in German patients with lung cancer: risk factors associated with 30-and 60-day mortality;Clinical and Experimental Medicine;2023-09-12

3. Thirty-Day Mortality Following Systemic Anticancer Therapy: Evaluating Risk Factors Without Selection Bias in a Real-World, Population-Based Cohort From 2009 to 2019;Clinical Oncology;2022-08

4. 30- und 90-Tage-Letalität bei Patienten mit Lungenkarzinom im Stadium IV in Abhängigkeit der Primärtherapie;TumorDiagnostik & Therapie;2022-06

5. Estimating the Impact of Delayed Access to Oncology Drugs on Patient Outcomes in Canada;Oncology and Therapy;2022-03-01